Evaluasi Nevirapine pada Terapi ARV Tahun Pertama dan Kedua Terhadap Fungsi Hati di Puskesmas Kecamatan Cilandak: Studi Kadar SGOT dan SGPT
Abstract
Anti-Retroviral Therapy (ART) is still the best medication for preventing and defeating the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) infection. However, the overall treatment needs a perpetual process and monitoring for effect. Nevirapine, one of the ART regimens, was recommended for use due to its high efficacy, even though it was suspected of causing liver hepatotoxicity. Liver disorders can be diagnosed by examining SGOT and SGPT blood levels in HIV/AIDS patients. The study aimed to monitor the effect of using Nevirapine on SGOT and SGPT blood levels in the first and second years of administration. This observational study with a cross-sectional design of Nevirapine users in Puskesmas Cilandak was from January 2019 to December 2022. The subject of the study was 113 respondents in total, with 40 respondents administered for one year of Nevirapine and 73 administered for two years. The one-year administration of Nevirapine showed that the abnormal SGOT and SGPT blood level in HIV/AIDS patients was equal to their baseline measurement (2.50%). On the other hand, the two years administration showed an increasing number of SGOT (30.20%) and SGPT (60.28%) in the blood. Spearman’s rank test was tested to check the correlation between the increasing level of SGOT and SGPT during the therapy, showing that SGOT and SGPT increased from one year to two years of the administration of Nevirapine with 0.33 (p<0.05) and 0.56 (p<0.05), respectively. The increasing SGOT and SGPT blood levels indicated a liver disorder. Yet another profound approach to examination needs to be done furthermore. Nevirapine administration to HIV/AIDS patients must be monitored perpetually to prevent further liver damage.
References
Amelia, M., Hadisaputro, S., Laksono, B., Anies dan Sofro, M. A. U. 2016. Faktor risiko yang berpengaruh terhadap kejadian HIV/AIDS pada laki-laki umur 25-44 tahun di kota Dili, Timor Leste. Jurnal Epidemiologi Kesehatan Komunitas 1(1): 39-47.
Andayani, P. L., Santoso, K., Kusumorini, N., Satyaningtijas, A. S. dan Supriyani, A. 2016. Bioma 12(1): 60-68.
Augustha, A. B., Wahab, Z. dan Ratnaningrum, K. 2018. Perubahan kadar hemoglobin dan nilai enzim aminotransferase pada terapi antiretriviral lini pertama. Ibnu Sina Biomedika 2(1): 1-6.
Ditjen P2P. 2021. Laporan perkembangan HIV AIDS dan penyakit infeksi menular seksual (PIMS) triwulan I tahun 2021. https://siha.kemkes.go.id/portal/files_upload/Laporan_TW_I_2021_FINAL.pdf. Diakses tanggal 23 Maret 2023.
Eckhardt, B. J. dan Gulick, R. M. 2017. Drugs for HIV infection. Infectious disease pp. 1300-1301.
Fan-Havard, P., Liu, Z., Chou, M., Ling, Y., Barrail-Tran, A., Haas, D. W. dan Taburet, A. 2013. Pharmacokinetics of Phase I Nevirapine Metabolites Following a Single Dose and at Steady State. Antimicrob Agents Chemother 57(5): 2154-2160.
Firdaus, J., Febianti, Z., Hidayat, M. R. F. dan Sakinah, E. N. 2022. Efek Neem Gum (Azadiracthta indica) terhadap kadar SGOT SGPT tikus Wistar yang diinduksi Diazinon. Journal of Nutrition College 11(3): 258-263.
Giacomelli, A., Riva, A., Falvella, F. S., Oreni, M. L., Cattaneo, D., Cheli, S., Renisi, G., Di Cristo, V., Lupo, A., Clementi, E., Rusconi, S., Galli, M. dan Ridolfo, A. L. 2018. Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients reciving nevirapine-based antiretroviral therapy. BMC Infectious Disease
Hidayat, R., Amir, H., Agus, A. I. dan Hisyam, M. 2023. Pengaruh lama pemberian obat antoretroviral terhadap sel CD4 pada penderita HIV/AIDS di Makassar Indonesia. An Idea Nursing Journal 2(1): 24-30.
Kementerian Kesehatan RI. 2019. Laporan perkembangan HIV AIDS dan penyakit infeksi menular seksual (PMS) triwulan II tahun 2019. Direktorat Pencegahan dan Pengendalian Penyakit, Jakarta.
Kurniawati, I., Nurmasitoh, T. dan Yahya, T. N. 2015. Effect of giving ethanol multistep doses to level SGPT and SGOT in wistar rat (Rattus norvegicus). Jurnal Kedokteran dan Kesehatan Indonesia 7(1): 30-35.
Meriyani, H., Udayani, N. N. W. dan Adrianta, K. A. Evaluasi fungsi hati pada pasien HIV/AIDS dengan terapi ARV di RSUD Mangusada. Jurnal Ilmiah Medicamento 4(2): 113-117.
Nursalam, Kurniawati, N. D., Misutamo, Solikhah, F. K. 2018. Asuhan keperawatan pada pasien terinfeksi HIV/AIDS ed. 2. Salemba Medika, Jakarta.
Oladipo, E. K., Afolabi, A. Y., Omomowo, I. O., Oloke, J. K. dan Awoyelu, E. H. 2016. Histological and biochemical markers of the liver of male wistar rats on oral administration of nevirapine suspension. African Journal of Clinical and Experimental Microbiology 17(1): 53-61.
Panel on Antiretroviral Guidelines for Adults and Adolescents. 2023. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://clinicalinfo.hiv.gov.en/guidelines/adult-and-adolescent-arv. Diakses tanggal 23 Maret 2023.
Pathania, S., Kaur, M., Kumar, S., Sashindran, V. K. dan Puri, P. 2017. A cross-sectional study of liver function tests in HIV-infected persons on western India. Med J Armed Forces India 73(1): 23-28.
Rahakbauw, N. 2016. Dukungan keluarga terhadap kelangsungan hidup ODHA (orang dengan HIV/AIDS). Insani 3(2): 64-82.
Rehman, N. dan Nguyen, H. Nevirapine dalam StatPearls (internet). https://www.ncbi.nlm.nih.gov/books/NBK554477/. Diakses tanggal 23 Maret 2023.
Rohmatullailah, D. dan Fikriyah, D. 2021. Faktor risiko kejadian HIV pada kelompok usia produktif di Indonesia. Bikfokes 2(1): 45-59.
Sarifatun. 2022. Literature review: efektivitas pemberian terapi antiretroviral dengan pemeriksaan cluster of differentiation 4 (CD4) pada pasien HIV. Universitas ‘Aisyiyah Yogyakarta, Yogyakarta.
Shanyengana, L. P., Mukesi, M., van der Colf, B. E. dan Moyo, S. R. 2016. Serum alanine aminotransferase elevations in HIV positive patients on antiretroviral therapy in Namibia. World Journal of AIDS 6(3): 101-110.
Sinaga, H. dan Hasim, M. H. 2019. Pemeriksaan fungsi hati pada penderita HIV dengan terapi ARV ≥ 6 bulan di Rumah Sakit Marthen Indey (RSMI) Jayapura. Jurnal Riset Kesehatan 8(1): 28-34.
Yunior, N. dan Wardani, I. K. F. 2018. Faktor-faktor yang berhubungan dengan kejadian HIV/AIDS di RSUD Kabupaten Bekasi tahun 2018. Stikes Medika Cikarang, Bekasi.
Copyright (c) 2023 IFI Cabang Kota Bekasi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Submission Preparation Checklist
As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
- I hereby declare that this submission is my own work.
- I hereby stated that this manusrcipt have no plagiarism matter.
- I declare the submission has no potential conflict of interest.
- I hereby stated that this manusrcipt have never been previously published in any other scientific publication and not being under reviewing process of any other scientific publication.
- The submitted manuscript contains no least than 2.000 words and not exceed 25 pages A4 including figures and tables, without any appendixes.
- The submitted manuscript has been written using Open Office Text Document (.odt) or Microsoft Word (.doc/.docx).
- Title already brief and concise, written in English, and less than 15 words.
- Abstract already brief and concise and not exceed 150 words in English.
- Keywords are written in English, between three to five phrase.
- The manuscript structure already consist: Introduction, Method/Material, Result and Discussion, Conclusion, Acknowledgement, and References.
- References are written according the writing style of MEV. The primary references are no less than 80% from at least fifteen sources and had been taken from the late ten year publications.
- The instructions in Ensuring a Blind Review have been followed to the submitted manuscript.
- (At least) two scientific referees have been suggested in "Comments for the Editor" textbox in the bottom of this page.
Copyright Notice
Retained Rights/Terms and Conditions of Publication
1. As an author you (or your employer or institution) may do the following:
- make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use;
- make copies and distribute such copies (including through e-mail) of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically, e.g. via an e-mail list or list server);
- present the article at a meeting or conference and to distribute copies of the article to the delegates attending such meeting;
- for your employer, if the article is a ‘work for hire’, made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company use (e.g. training);
- retain patent and trademark rights and rights to any process, procedure, or article of manufacture described in the article;
- include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially);
- use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of the article in the journal); and prepare other derivative works, to extend the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal;
- may reproduce or authorize others to reproduce the article, material extracted from the article, or derivative works for the author’s personal use or for company use, provided that the source and the copyright notice are indicated, the copies are not used in any way that implies RCEPM-LIPI endorsement of a product or service of any employer, and the copies themselves are not offered for sale.
All copies, print or electronic, or other use of the paper or article must include the appropriate bibliographic citation for the article’s publication in the journal.
2. Requests from third parties
Although authors are permitted to re-use all or portions of the article in other works, this does not include granting third-party requests for reprinting, republishing, or other types of re-use. Requests for all uses not included above, including the authorization of third parties to reproduce or otherwise use all or part of the article (including figures and tables), should be referred to RCEPM-LIPI by going to our website athttp://telimek.lipi.go.id.
3. Author Online Use
- Personal Servers. Authors and/or their employers shall have the right to post the accepted version of articles pre-print version of the article, or revised personal version of the final text of the article (to reflect changes made in the peer review and editing process) on their own personal servers or the servers of their institutions or employers without permission from RCEPM-LIPI, provided that the posted version includes a prominently displayed RCEPM-LIPI copyright notice and, when published, a full citation to the original publication, including a link to the article abstract in the journal homepage. Authors shall not post the final, published versions of their papers;
- Classroom or Internal Training Use. An author is expressly permitted to post any portion of the accepted version of his/her own articles on the author’s personal web site or the servers of the author’s institution or company in connection with the author’s teaching, training, or work responsibilities, provided that the appropriate copyright, credit, and reuse notices appear prominently with the posted material. Examples of permitted uses are lecture materials, course packs, e-reserves, conference presentations, or in-house training courses;
- Electronic Preprints. Before submitting an article to an MEV Journal, authors frequently post their manuscripts to their own web site, their employer’s site, or to another server that invites constructive comment from colleagues. Upon submission of an article to MEV Journal, an author is required to transfer copyright in the article to RCEPM-LIPI, and the author must update any previously posted version of the article with a prominently displayed RCEPM-LIPI copyright notice. Upon publication of an article by the RCEPM-LIPI, the author must replace any previously posted electronic versions of the article with either (1) the full citation to the work with a Digital Object Identifier (DOI) or link to the article abstract in MEV journal homepage, or (2) the accepted version only (not the final, published version), including the RCEPM-LIPI copyright notice and full citation, with a link to the final, published article in journal homepage.
4. Articles in Press (AiP) service
RCEPM-LIPI may choose to publish an abstract or portions of the paper before we publish it in the journal. Please contact our Production department immediately if you do not want us to make any such prior publication for any reason, including disclosure of a patentable invention.
5. Author/Employer Rights
If you are employed and prepared the article on a subject within the scope of your employment, the copyright in the article belongs to your employer as a work-for-hire. In that case, RCEPM-LIPI assumes that when you sign this Form, you are authorized to do so by your employer and that your employer has consented to the transfer of copyright, to the representation and warranty of publication rights, and to all other terms and conditions of this Form. If such authorization and consent has not been given to you, an authorized representative of your employer should sign this Form as the Author.
6. RCEPM-LIPI Copyright Ownership
It is the formal policy of RCEPM-LIPI to own the copyrights to all copyrightable material in its technical publications and to the individual contributions contained therein, in order to protect the interests of the RCEPM-LIPI, its authors and their employers, and, at the same time, to facilitate the appropriate re-use of this material by others. RCEPM-LIPI distributes its technical publications throughout the world and does so by various means such as hard copy, microfiche, microfilm, and electronic media. It also abstracts and may translate its publications, and articles contained therein, for inclusion in various compendiums, collective works, databases and similar publications
Every accepted manuscript should be accompanied by "Copyright Transfer Agreement" prior to the article publication.